Six Parkinsonian patients on long term levodopa therapy complained of shortlived deterioration of Parkinsonian symptoms immediately after levodopa intake. After withdrawal of the drug overnight, and following an oral challenge with levodopa/carbidopa (250125) in all six cases, and with subcutaneous apomorphine (3 mg) in two, deterioration below base line levels of disbility were observed which would not be explained by loss of sleep benefit. This occurred [10] [11] [12] [13] [14] [15][16][17][18][19][20] (range 7-26) and all were experiencing motor fluctuations and dyskinesias. Four of the patients had biphasic dyskinesias and the remaining two had interdose dyskinesias. Three of the patients were receiving apomorphine subcutaneously in addition to levodopa therapy. The mean daily levodopa dose was 600 mg (range 300-800).
Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease During the test three patients also exhibited end-of-dose motor inhibitory effects, two had interdose dyskinesias and four biphasic dyskinesias. There was no correlation between the timing of the initial motor deterioration and the onset of biphasic dyskinesias. Figure 3 shows the relationship between the increase in tremor which was the main component of the beginning-of-dose motor deterioration in one patient and the onset of biphasic dyskinesias. (-ŝ wr i2f 150 1BO21024(, common and under-reported phenomenon, probably because it is not easy to demonstrate objectively. In some of the patients, deterioration was striking and apparent to both the patient and observer. Deterioration in the motor assessments was also considered to be significant. Two baseline motor examinations were carried out before each challenge test and there was no suggestion of deterioration between the first and second observation, making it improbable that the observed phenomenon was due to sleep benefit wearing off. We also studied a further six patients who did not complain of beginning-of-dose deterioration and were unable to demonstrate the phenomenon. No obvious clinical differences were seen between the two groups.
End-of-dose motor deterioration has been studied carefully2 but beginning-of-dose motor deterioration, although postulated as likely to occur, has not been specifically studied 
